Publisher Correction: Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients

Elsebaie, Maha A. T.; Amgad, Mohamed; Elkashash, Ahmed; Elgebaly, Ahmed; Ashal, Gehad Gamal E. l.; Shash, Emad; Elsayed, Zeinab

doi:10.1038/s41598-018-29513-4

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is still no consensus on standard chemotherapy for adult ERMS. [ 14 ] In 2017, a group of sarcoma experts was investigating to set up treatment guidelines for managing RMS. For high risk RMS patients, combined use of isophosphamide and epirubicin, or irinotecan and vindesine sulfate, are recommended.…”

Section: Discussionmentioning

confidence: 99%

An uncommon perineal embryonal rhabdomyosarcoma in adult: A case report

Yao

et al. 2022

Medicine

View full text Add to dashboard Cite

Rationale: Embryonal rhabdomyosarcoma (ERMS) is a major subtype of rhabdomyosarcoma, mainly affect children. There is seldom report for perineal ERMS in adults, since its rare location and the age. Patient concerns: A 20-year old male adult was admitted due to the perineal mass. Diagnoses: Diagnosis by histopathological examination of the biopsy sample was ERMS. Magnetic resonance imaging showed the tumor was found in the perineal region, with metastasis to pelvic cavity, right testis, lymph nodes and bone. Interventions: The patient received Isophosphamide and Epirubicin for 4 cycles, followed by Irinotecan and Vindesine Sulfate for 2 cycles, then cisplatin, Dacarbazine and Apatinib for 3 cycles. Outcome: The patient showed no response to chemotherapy. Lessons: Perineal ERMS in adults is very rare. There is still no standard therapy for adult ERMS. Personalized therapy might be promising treatment for each individual.

show abstract

Section: Discussionmentioning

confidence: 99%

An uncommon perineal embryonal rhabdomyosarcoma in adult: A case report

Yao

et al. 2022

Medicine

View full text Add to dashboard Cite

show abstract

“…There are multimodality treatment options for adult RMS, including surgery, radiation therapy for control of residual bulk or microscopic tumor and systemic combination chemotherapy for primary cytoreduction and eradication of gross and micrometastases. [ 18 ] Complete surgical resection is the mainstay of curative therapy to ablate the disease for early tumor stage in the absence of distant metastases. All patients with RMS must receive combination chemotherapy as soon as diagnosis is made or after resection.…”

Section: Discussionmentioning

confidence: 99%

Primary alveolar rhabdomyosarcoma of retrorectal-presacral space in an adult patient

Zhu¹,

Sui²,

Tang

et al. 2019

Medicine

View full text Add to dashboard Cite

Rationale:Rhabdomyosarcoma (RMS) has known as a highly malignant soft tissue sarcoma, representing 5% to 10% of all solid tumors in childhood. Alveolar rhabdomyosarcoma (ARMS) of the retrorectal-presacral space is an extremely rare lesion for adult, no study has been reported in the English literature.Patient concerns:A 51-year-old male presented with abdominal pain for 1 month, significantly worse when having a bowel movement.Diagnosis:Computed tomography (CT) and magnetic resonance imaging (MRI) of the pelvis showed a solid-cystic, enhancing lesion of dimension located in retrorectal-presacral space. The surgical specimen was reported as ARMS after pathological evaluation.Interventions:The tumor was complete surgical resection, and after surgery, the patient was treated with combination chemotherapy.Outcomes:At 23 months follow up, the patient was asymptomatic with no evidence of metastases or local recurrence.Lessons:Improvements in imaging in addition to early surgical intervention and chemotherapy treatment are crucial to improve survival chances against RMS.

show abstract

“…A possible reason for lower survival in adult RMS is that the most common histological subtype in adults (pleomorphic) is not as responsive to chemotherapy as the embryonal or alveolar subtypes (8,21,25,26). Another possibility is that the frequency of the pleomorphic subtype increases with advancing age and stage (9).…”

Section: Free (Dfs) (A C) and Overall (Os) (B D) Survival Outcomes Of...mentioning

confidence: 99%

Prognostic Factors and Treatment Outcomes of Adult Patients With Rhabdomyosarcoma After Multimodality Treatment

et al. 2019

View full text Add to dashboard Cite

Background: Adults with rhabdomyosarcoma (RMS) have a worse clinical outcome compared to pediatric cases. In the present study, the failure pattern and clinical outcome of adult patients with RMS who received multimodality treatment at our Institution was assessed. Patients and Methods: Data were retrospectively recorded and analyzed from 20 adult patients, aged 19 years or more, who were treated for RMS at our Institution between 2004 and 2015. Disease-free (DFS) and overall (OS) survival after starting treatment were calculated using the Kaplan-Meier method. The relationship of these outcome measures with the following variables was then assessed: Primary site, tumor stage, lymph node involvement, histological subtype, radiotherapy (RT), and duration of chemotherapy. Results: Sixteen patients had localized RMS, and four had metastatic disease. For the whole patient cohort, the 3-year DFS and OS rates were 20%, and 45%, respectively. Patients with alveolar histological subtype had a better 3-year OS than those with other subtypes (p=0.038). The median OS rates for those with localized and metastatic disease were 53.2 (95% confidence interval(CI)=14.7-91.8) months, and 21.7 (95% CI=0-45.7) months, respectively (p=0.047). In patients with localized RMS, those who received RT (n=13) had a better median DFS (24.6 versus 6.0 months, p=0.009) and OS (53.2 versus 11.4 months, p=0.009) than those who did not (n=3).For patients receiving RT, concurrent chemotherapy with vincristine and cyclophosphamide (n=11) was associated with better 3-year DFS (36.4% versus 0%, p<0.001) and OS (81.8% versus 0%, p<0.001) compared with RT alone (n=2). Administration of chemotherapy for more than 19 weeks significantly correlated with better 3-year DFS (44% versus 0%, p=0.001) and OS (53.3% versus 0%, p<0.001) in those with localized RMS. Conclusion: In addition to staging and histological subtype, our results indicate that concurrent chemoradiotherapy and longer duration of chemotherapy were associated with significantly improved DFS and OS in adult patients with localized RMS.Rhabdomyosarcoma (RMS) is the most common soft-tissue malignancy, accounting for 4-5% of cancer cases in children (1). In Taiwan, soft-tissue sarcoma accounted for approximately 40% of all pediatric cancers diagnosed between 1996 and 2010, with RMS comprising 6% of all pediatric soft-tissue sarcomas (2). RMS is far less common in adults (2). Although most cases occur in children younger than 10 years, adult RMS still accounted for 41% of all RMS cases in the Surveillance, Epidemiology and End Results (SEER) database between 1973 and 2005 (3). Pediatric patients with RMS are typically treated within clinical studies or by standard protocols. In the United States, the Intergroup Rhabdomyosarcoma Study Group (IRSG; now the Children's Oncology Group Soft-Tissue Sarcoma Committee) organized a series of studies incorporating multimodality treatment (chemotherapy, surgery, and radiotherapy) to treat pediatric RMS, and the 5-year overall survival (OS) after treatment cle...

show abstract

Publisher Correction: Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients

Abstract: A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

Cited by 4 publications

References 0 publications

An uncommon perineal embryonal rhabdomyosarcoma in adult: A case report

An uncommon perineal embryonal rhabdomyosarcoma in adult: A case report

Primary alveolar rhabdomyosarcoma of retrorectal-presacral space in an adult patient

Prognostic Factors and Treatment Outcomes of Adult Patients With Rhabdomyosarcoma After Multimodality Treatment

Contact Info

Product

Resources

About